Recently, Hutchinson, et al.18 utilized a similarly integrative approach to identify new fusions involving BRAF in melanomas potentially sensitive to MEK inhibition by Trametinib using ectopically expressed BRAF fusion gene in the embryonic kidney HEK293 cells. This evidence concerns the gene MAP2K7 and melanoma.